Spyre Therapeutics, Inc. (NASDAQ:SYRE) fell 13% to $94 on August 26, 2026, but the sell-off sharply overreacted to the underlying data. The company’s SPY072 asset, tested in a rheumatoid arthritis sub-study of the Phase 2 SKYWAY trial reported August 25, cleared statistical significance versus placebo on one or more of the primary DAS28-CRP endpoints and on ACR20 and ACR50, with a clean safety profile. It simply did not clear Spyre’s internal threshold to advance as an RA monotherapy. The company chose not to prioritize the program as RA monotherapy. This secondary asset’s demotion was treated as a crack in the franchise. And that’s where the problem is.
The Market Sold the Sideshow
What was really driving the value was not the RA. Management chose not to prioritize SPY072 as a standalone RA therapy despite the drug hitting multiple endpoints. This is not a clean efficacy failure but a portfolio decision. The headline over the deprioritization managed to knock approximately $1 billion off an $8 billion company, while the data table underneath it was disregarded. Reading it the same way, Stifel reiterated a Buy rating and a $123 target on August 26, 2026. Deutsche Bank and Wedbush lowered their price targets on the stock to $127 and $123, respectively, following the SPY072 results. The analysts continue to stick to their Buy and Outperform ratings.
The Main Engine Already Worked
Spyre’s valuation rests on its SKYLINE inflammatory-bowel-disease (IBD) platform, which continues to run. The company’s lead ulcerative-colitis antibody, SPY001, delivered a 9.2-point reduction in the Robarts Histopathology Index (p less than 0.0001) in Phase 2, with 40% clinical remission and 51% endoscopic improvement. With SPY001 producing results that support a potential best-in-class profile against historical benchmarks, alongside SPY002 and Spyre’s combination strategy, the core IBD thesis remains intact. The next major SKYLINE data readout, due in September, will reveal the company’s true position.
The Bear Case Is Also Real
With an approximately $8 billion market capitalization, no approved products and no product-sales revenue, Spyre is already pricing in its clinical success. Insider Monkey’s hedge funds database shows that the institutional interest is improving, with 57 funds holding SYRE in Q2 2026, up from 36 in Q1. Short interest remains elevated at 13.81% of float. The company holds approximately $1.15 billion in cash to fund operations into the second half of 2029, revealing that the real risk is not financing but valuation.
Bottom Line
In Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s case, two realities exist at once. The market selloff has punished the wrong clinical trial, increasing the dependency on the September SKYLINE data for decision-making.
While we acknowledge the potential of SYRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
[/im-yf-promo]
READ NEXT: Airbnb Just Hit a Four-Year High. The Downgrade Says That’s the Problem and T-Mobile (TMUS), The Market’s Favorite Telecom Just Got Downgraded — and the Reason Should Worry Bulls
Disclosure: None. Follow Insider Monkey on Google News.
